Attorney Docket: WYS-007.01

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- 1. (Previously Presented) A method of downmodulating an autoimmune response in a subject having type I diabetes, comprising administering an effective amount of an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject, such that an autoimmune response in the subject is downmodulated.
- 2. (Original) The method of claim 1, wherein the antigen binding portion is a scFv molecule or an Fab fragment.
 - 3. (Original) The method of claim 1, wherein the antigen binding portion is humanized.
 - 4. (Original) The method of claim 1, wherein the antigen binding portion is fully human.
 - 5-8. (Canceled)
- 9. (Previously Presented) A method of downmodulating an ongoing immune response in a subject having type I diabetes comprising administering an effective amount of an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject, such that an ongoing autoimmune response in the subject is downmodulated.
- 10. (Original) The method of claim 9, wherein the antigen binding portion is a scFv molecule or an Fab fragment.
- 11. (Original) The method of claim 9, wherein the antigen-binding portion is humanized.
- 12. (Original) The method of claim 9, wherein the antigen-binding portion is fully human.
 - 13-27. (Canceled)
- 28. (Previously Presented) The method of claim 2, wherein the antigen binding portion is a scFv molecule.
 - 29. (Previously Presented) The method of claim 28, wherein the scFv molecule is PV1.
- 30. (Previously Presented) The method of claim 10, wherein the antigen binding portion is a scFv molecule.
 - 31. (Previously Presented) The method of claim 30, wherein the scFv molecule is PV1.

B3481057.2 - 3 -

Attorney Docket: WYS-007.01

- 32. (Original) A method of downmodulating a CD28-mediated interaction in a subject having type I diabetes comprising administering an effective amount of an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject, such that a CD28 interaction in the subject is downmodulated.
- 33. (Original) The method of claim 32, wherein the antigen binding portion is a scFv molecule or an Fab fragment.
- 34. (Previously Presented) The method of claim 32, wherein the antigen-binding portion is humanized.
- 35. (Previously Presented) The method of claim 32, wherein the antigen-binding portion is fully human.
- 36. (Original) The method of claim 32, wherein the antigen binding portion is a scFv molecule.
 - 37. (Previously Presented) The method of claim 33, wherein the scFv molecule is PV1.
- 38. (New) A method of downmodulating an autoimmune response in a subject having type I diabetes, comprising administering an effective amount of an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject, such that an autoimmune response in the subject is downmodulated, wherein the antigen binding portion is a scFv molecule, and wherein the scFV molecule is PV1.
- 39. (New) A method of downmodulating an ongoing immune response in a subject having type I diabetes comprising administering an effective amount of an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject, such that an ongoing autoimmune response in the subject is downmodulated, wherein the antigen binding portion is a scFv molecule, and wherein the scFV molecule is PV1.
- 40. (New) A method of downmodulating a CD28-mediated interaction in a subject having type I diabetes comprising administering an effective amount of an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject, such that a CD28 interaction in the subject is downmodulated, wherein the antigen binding portion is a scFv molecule, and wherein the scFV molecule is PV1.

B3481057.2 - 4 -